Article Details
Retrieved on: 2022-06-02 15:57:08
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Under the licensing and collaboration deal, Roche will assume the development of camonsertib, also known as RP-3500, a potent and selective oral small ...
Article found on: www.pharmalive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here